Business Context and Reporting Period
Company: Novavax, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 29, 2017
Event: The Company filed a prospectus supplement to sell up to $75,000,000 of common stock through "at the market offerings" pursuant to an At Market Issuance Sales Agreement with B. Riley FBR, Inc.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses solely on the authorization of a potential equity offering.
Material Changes
The material change reported is the execution of a new sales agreement allowing for the potential issuance of shares. The filing explicitly states that the Company cannot provide assurances that it will issue any shares under this agreement.
Guidance, Outlook, and Risks
- Outlook: The Company may sell shares from time to time based on market conditions and instructions to the Sales Agent.
- Risks/Contingencies: There is no guarantee that any shares will be sold. The description of the agreement is qualified by reference to the full text of the agreement attached as Exhibit 1.1.
- Legal Counsel: Ropes & Gray LLP provided a legal opinion regarding the shares.
Investor Verification Checklist
- Verify the total number of shares authorized for sale under the $75,000,000 cap.
- Review the full "At Market Issuance Sales Agreement" (Exhibit 1.1) for commission fees and termination clauses.
- Monitor subsequent filings to determine if and when shares are actually issued under this agreement.
- Check the Company's latest 10-K or 10-Q for current cash position and liquidity needs driving this potential offering.